Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?

Christina M Wyatt; Glenn M Chertow

doi:10.1016/j.kint.2016.06.021

Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?

Kidney Int. 2016 Sep;90(3):460-2. doi: 10.1016/j.kint.2016.06.021.

Authors

Christina M Wyatt¹, Glenn M Chertow²

Affiliations

¹ Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: christina.wyatt@mssm.edu.
² Department of Medicine, Division of Nephrology, Stanford School of Medicine, Stanford, California, USA.

PMID: 27521103
DOI: 10.1016/j.kint.2016.06.021

Abstract

The recently published Heart Outcomes Prevention Evaluation trial (HOPE-3) demonstrated no benefit of lowering blood pressure with candesartan and hydrochlorothiazide in persons at intermediate cardiovascular risk and with adequate blood pressure control as determined by the enrolling physician. The results of Systolic Blood Pressure Intervention Trial (SPRINT) and HOPE-3 highlight the importance of considering differences in study design and patient population when interpreting the results of clinical trials.

MeSH terms

Antihypertensive Agents*
Blood Pressure / drug effects
Cardiovascular Diseases*
Humans
Hydrochlorothiazide
Hypertension
Risk Factors

Substances

Antihypertensive Agents
Hydrochlorothiazide